Declining incidence rate of tuberculosis among close contacts in five years post-exposure: a systematic review and meta-analysis

Du, Ying; He, Yijun; Zhang, Haoran; Shen, Fei; Guan, Ling; Xin, Henan; He, Yongpeng; Cao, Xuefang; Feng, Boxuan; Quan, Zhusheng; Liu, Jianmin; Gao, Lei

doi:10.1186/s12879-023-08348-z

Table 2 Baseline and follow-up characteristics of close contacts of all included studies

From: Declining incidence rate of tuberculosis among close contacts in five years post-exposure: a systematic review and meta-analysis

First author, publish year	Baseline close contact survey				Incidence of active TB during follow up
	TB prevalence^a		MTB infection prevalence		Follow up period	Incidence of active TB during follow up(%)	TB Cases^b	Close contacts (person years)
	n/N (%)	Diagnosis	n/N (%)	Testing	Follow up period	Incidence of active TB during follow up(%)	TB Cases^b	Close contacts (person years)
Yassin MA, 2020 [4]	NA	Microbiologically confirmed / Clinically confirmed	NA	NA	1 year	2.74	41	1,496
Yassin MA, 2020 [4]	NA	Microbiologically confirmed / Clinically confirmed	NA	NA	2 years	1.79	53	2,965
Araujo CN, 2020 [13]	20/495 (4.04)	Microbiologically confirmed/ Clinically confirmed	351/435 (80.69)	TST ≥ 5 mm	2 years	1.11	3	270
Saunders MJ, 2019 [5]	NA	Microbiologically confirmed/ Clinically confirmed	NA	NA	1 year	2.91	76	2,611
					2 years	2.36	121	5,130
					5 years	1.43	174	12,150
Huerga H, 2019 [14]	3/150 (2.00)	Microbiologically confirmed	NA	NA	2 years	0	0	246
Benjumea-Bedoya D, 2019 [15]	NA	Microbiologically confirmed/ Clinically confirmed	243/458 (53.06)	TST > 5 mm	2 years	1.49	31	2,080
Becerra MC, 2019 [16]	NA	Microbiologically confirmed/ Clinically confirmed	4,488/1,016 (44.17)	TST ≥ 10 mm	1 year	3.13	318	10,160
Reichler MR, 2018 [17]	108/4,490 (2.41)	Microbiologically confirmed	NA	TST ≥ 5 mm	1 year	1.45	64	4,419
					2 years	0.79	69	8,766
					5 years	0.35	75	21,654
Martinez L, 2018 [18]	126/1,718 (7.33)	Microbiologically confirmed/ Clinically confirmed	1,261/1,718 (70.78)	TST ≥ 5 mm	2 years	0.70	24	3,436
Baliashvili D, 2018 [19]	64/3,133 (2.04)	Microbiologically confirmed	393/1,157 (33.97)	TST ≥ 10 mm	1 year	1.66	52	3,133
Sharma SK, 2017 [20]	NA	Microbiologically confirmed/ Clinically confirmed	787/1,511 (52.08); 917/1,511 (20.09)	TST ≥ 10 mm /IGRA +	2 years	2.51	76	3,022
Puma DV, 2017 [21]	NA	NA	38/103 (36.89)	TST ≥ 5 mm	5 years	0.19	1	515
Munoz L, 2017 [22]	NA	NA	223/321(69.47); 184/340(54.11)	TST ≥ 10 mm /IGRA +	5 years	0.09	3	3305
Triasih R, 2015 [23]	25/269 (9.29)	Microbiologically confirmed	100/269 (37.17)	TST ≥ 10 mm	1 year	2.76	4	145
Chakhaia T, 2014 [24]	30/869 (3.45)	Microbiologically confirmed	212/402 (52.74)	TST ≥ 5 mm	1 years	1.08	9	833
Chakhaia T, 2014 [24]	30/869 (3.45)	Microbiologically confirmed	212/402 (52.74)	TST ≥ 5 mm	2 years	1.32	17	1,285
Singh J, 2013 [25]	52/1,608 (3.23)	Microbiologically confirmed	NA	NA	1 years	1.41	27	1,914
Singh J, 2013 [25]	52/1,608 (3.23)	Microbiologically confirmed	NA	NA	2 years	0.86	31	3,621
Haldar P, 2013 [26]	6/1,671 (0.36)	Microbiologically confirmed/ Clinically confirmed	215/851 (25.26)	IGRA +	2 years	1.29	43	3,342
Wang JY, 2012 [27]	17/600 (2.83)	NA	176/583 (30.19)	IGRA +	2 years	0.82	9	1,102
Song S, 2012 [28]	NA	Microbiologically confirmed/ Clinically confirmed	270/1,826 (14.79)	TST ≥ 10 mm	2 years	0.48	16	3,310
Denholm JT, 2012 [29]	NA	NA	49/552 (8.86)	TST ≥ 10 mm	2 years	0.18	2	1,118
Becerra MC, 2011 [30]	117/4,503 (2.60)	NA	NA	NA	1 year	3.17	140	4,423
Becerra MC, 2011 [30]	117/4,503 (2.60)	NA	NA	NA	2 years	2.14	187	8,726
Lienhardt C, 2010 [31]	14/2,762 (0.51)	Microbiologically confirmed/ Clinically confirmed	1,591/2,458 (64.73)	TST ≥ 10 mm	2 years	0.93	52	5,606
del Corral H, 2009 [32]	8/2,060 (0.39)	NA	331/502 (65.94); 1,310/1,977 (66.26)	TST ≥ 10 mm/ IGRA +	2 years	0.94	37	3,934
Cailleaus M, 2009 [33]	NA	Clinically confirmed	460/998 (46.09)	TST ≥ 5 mm	2 years	1.65	22	1,334
Hill PC, 2008 [34]	33/2,381 (1.39)	Microbiologically confirmed/ Clinically confirmed	NA	NA	1 years	0.64	15	2,326
Hill PC, 2008 [34]	33/2,381 (1.39)	Microbiologically confirmed/ Clinically confirmed	NA	NA	2 years	0.58	26	4,518
Diel R, 2008 [35]	3/629 (0.48)	Microbiologically confirmed	110/601 (18.30); 66/601 (10.98)	TST ≥ 10 mm/ IGRA +	2 years	0.43	5	1,150
Lemos AC, 2004 [36]	7/269 (2.6)	NA	136/269 (50.56)	TST ≥ 10 mm	1 year	1.12	3	269
Bayona J, 2003 [37]	29/945 (3.07)	NA	NA	NA	5 years	1.57	72	4,590
Devadatta S, 1970 [38]	NA	Microbiologically confirmed/ Clinically confirmed	NA	NA	5 years	1.76	77	4,375
Kamat SR, 1966 [39]	NA	Microbiologically confirmed/ Clinically confirmed	NA	NA	5 years	2.85	62	2,175
Ramakrishnan CV, 1961 [40]	NA	Microbiologically confirmed/ Clinically confirmed	NA	NA	2 years	2.78	34	1,224
Andrews RH, 1960 [41]	50/693 (7.22)	Microbiologically confirmed	455/647 (70.32)	TST ≥ 5 mm	1 year	5.01	32	639

Abbreviation: IGRA Interferon gamma release assay, IGRA + IGRA positive, MTB Mycobacterium tuberculosis, NA Not available, TB Tuberculosis, TST Tuberculin skin test
^aMost articles reported active TB prevalence at baseline among close contacts including coprevalent disease which was defined as confirmed TB identified at baseline or within 3 months post exposure
^bMost articles defined incidence of active TB during follow up as incident TB without coprevalent disease

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us